Umang Pioneering Non-Invasive Breast Cancer Screening

Every October, Breast Cancer Awareness Month reminds us that early detection is not just important, it is life-saving. Today, technology is redefining how we confront this challenge. Leading the way is Umang Health Innovation, with solutions that make screening smarter, non-invasive, and accessible.

At the core of this breakthrough lies CaTS, a wearable thermal-sensor device seamlessly paired with Thermalyse, an AI-powered platform that maps subtle temperature variations across the breast surface. This powerful combination can identify the earliest signs of breast cancer, often long before traditional methods can detect them. It is not just innovation; it is hope, precision, and empowerment for millions of women worldwide.

The screening experience itself is a revolution: safe, touch-free, pain-free, and radiation-free. Women of all ages, including those under 40, can benefit. By transforming what was once an uncomfortable, clinical procedure into a private, empowering, and precise alternative to manual exams, Umang is rewriting the future of women’s health with equal parts science, empathy, and innovation.

In an exclusive conversation with The Interview World at Medicall, Sai Kiran Madderla, Sales & Business Development Manager at Umang Health Innovation Pvt. Ltd., delves deeper. He explains the science behind their non-invasive technology for breast cancer screening, outlines the pricing strategy, shares upcoming innovations designed to build on their current platform, and highlights the journey toward commercialization. His insights reveal not just a product, but a bold vision for accessible, next-generation women’s healthcare.

Q: Could you elaborate on the non-invasive breast cancer screening technology your startup has developed?

A: Umang Healthcare Innovation, a Hyderabad-based startup, is transforming breast cancer screening. Our technologies are patented through C-MET and MeitY, and we have received full certification from MeitY. We offer a non-invasive, radiation-free, and affordable device designed for early detection of breast cancer. Specifically, it identifies initial lumps in women over 21, making early intervention accessible and practical.

Unlike traditional imaging methods such as mammography, PET-CT, or MRI—which are costly, often inaccessible, and generally used for secondary screening—our device serves as a primary, initial screening tool.

Designed for convenience and privacy, it can be used at home without any compression, unlike mammography. The device is wearable: simply strap it on, connect it to the app, and the screening begins automatically.

Q: How does your technology screen for breast cancer, and what accuracy can patients and clinicians realistically expect compared to conventional methods?

A: This device functions like a thermostat, sensing subtle heat patterns in the body, similar to how PET-CT works. PET-CT detects heat through radiation to identify tumours and lumps.

Our technology applies the same principle but focuses specifically on the breast. Unlike mammography, which typically detects larger lumps, our device can identify extremely small anomalies, even as tiny as 0.1 mm. This allows women to pursue clinical correlation early, supporting proactive healthcare.

The device achieves a specificity of 86%, reflecting its high level of accuracy and reliability for initial breast cancer screening.

Q: What is your pricing strategy for this product, and can the device be reused multiple times?

A: Our solution consists of two components: a screening module and a device module. The device module is designed to accommodate all body types, offering four sizes from small to XL to ensure accurate screening for every woman.

The device is priced at approximately ₹7 lakh and comes with a three-year warranty. It is durable and reusable. One device can screen up to four women, provided the appropriate size attachments are used.

Q: At a price point of ₹7 lakhs per product, how do you plan to make this solution accessible and affordable for broader adoption?

A: Our business primarily operates on a B2B model, serving government institutions and organizations. For individual users, we offer per-screening services, including home visits. However, the majority of our operations and revenue focus on B2B engagements.

Q: What new innovations are you planning to build on top of this product?

A: Next, we are developing AI-enabled reporting. Currently, our software generates screening reports after the process is completed. Moving forward, we aim to produce reports instantly, as soon as the screening begins, by leveraging advanced AI technology. This real-time reporting capability is the focus of our ongoing development.

Q: Have you already commercialized this product, or are you still in the commercialization stage?

A: We have secured all ISO and CDSCO certifications. Already, several cancer hospitals are using our product in their medical camps.

Although our startup is just six months old, we are confident in our growth trajectory. We anticipate capturing a significant share of the market for initial breast cancer screening very soon.

Q: Do you have plans to export this product to international markets?

A: Currently, we are not focusing on exports. Our priority is to screen Indian women, given the vast size of our population.

Our goal is to reach every woman over the age of 21 for initial screening. In India, cancer is often detected at advanced stages, such as stage 3 or 4. We aim to identify cases early, up to ten years before they would typically be diagnosed.

This initiative is dedicated entirely to serving Indian women and improving early detection within the country.